Recent Updates
Recently added Catalysts
STRO

65th American Society of Hematology Annual Meeting and Exposition – Poster

Key Takeaway: The 65th American Society of Hematology Annual Meeting featured a presentation by Dr. Soheil Meshinch on Luveltamab Tazevibulin (LT, STRO-002), an antibody-drug conjugate targeting the folate receptor alpha. This study highlights its anti-leukemic activity in patients with relapsed or refractory CBFA2T3::GLIS2 acute myeloid leukemia (AML). The findings suggest potential therapeutic benefits for this challenging patient population.
Price reaction · baseline $35.7 (2023-12-08 close) · hit pre-market · 1 other STRO headline(s) in the window, move may be shared
day 0 close · peak
+0.8%

Market Sentiment Analysis

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~13 mo
Low dilution risk
Lead asset
STRO-004
Phase 1 · Head and Neck Squamous Cell Carcinoma HNSCC

Full Press Release Details

[et_pb_section fb_built=”1″ _builder_version=”4.16″ custom_padding=”0px||||false|false” global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_post_title author=”off” categories=”off” comments=”off” admin_label=”65th American Society of Hematology Annual Meeting and Exposition – Poster” _builder_version=”4.23.4″ title_level=”h2″ title_text_color=”#0c71c3″ title_font_size=”28px” title_letter_spacing=”1px” title_line_height=”1.4em” meta_text_color=”#000000″ global_colors_info=”{}”][/et_pb_post_title][et_pb_divider color=”#0badbc” divider_weight=”2px” _builder_version=”4.16″ global_colors_info=”{}”][/et_pb_divider][/et_pb_column][/et_pb_row][et_pb_row _builder_version=”4.17.1″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.17.1″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.23.4″ _module_preset=”default” hover_enabled=”0″ sticky_enabled=”0″ text_text_color=”#000000″ text_font_size=”19px”]
Anti-leukemic Activity of Luveltamab Tazevibulin (LT, STRO-002), a Novel Folate Receptor- α ( FR- α)- targeting Antibody Drug Conjugate (ADC) in Relapsed/Refractory CBFA2T3::GLIS2 AML
Presenter & Primary Author: Dr. Soheil Meshinch
[/et_pb_text][et_pb_button button_url=”https://www.sutrobio.com/wp-content/uploads/2024/02/Sutro_ASH-2023-Poster-Final.jpg” url_new_window=”on” button_text=”Presentation” button_alignment=”left” admin_label=”Presentation – Button” _builder_version=”4.23.4″ _module_preset=”default” custom_button=”on” button_text_size=”18px” button_text_color=”#0C71C3″ button_bg_color=”#FFFFFF” button_border_width=”1px” button_border_color=”#0C71C3″ button_border_radius=”3px” button_icon=”||divi||400″ button_icon_color=”#0C71C3″ button_on_hover=”off” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″][/et_pb_button][et_pb_image _builder_version=”4.23.4″ _module_preset=”default” title_text=”Sutro_ASH-2023-Poster-Final” src=”https://www.sutrobio.com/wp-content/uploads/2024/02/Sutro_ASH-2023-Poster-Final.jpg” hover_enabled=”0″ sticky_enabled=”0″][/et_pb_image][/et_pb_column][/et_pb_row][/et_pb_section]

Frequently Asked Questions

What is Luveltamab Tazevibulin?

Luveltamab Tazevibulin (LT, STRO-002) is a novel antibody-drug conjugate targeting the folate receptor alpha.

Who presented the findings at the ASH meeting?

The findings were presented by Dr. Soheil Meshinch.

What type of leukemia does the study focus on?

The study focuses on relapsed or refractory CBFA2T3::GLIS2 acute myeloid leukemia (AML).

What was the main finding of the presentation?

The main finding highlighted the anti-leukemic activity of Luveltamab Tazevibulin in AML patients.

Last updated: Dec 11, 2023